A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain.

Trial Profile

A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 03 Jun 2015 The EC approved RELISTOR (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, according to a Valeant Pharmaceuticals International and Progenics Pharmaceuticals media release.
    • 27 Apr 2015 The Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of methylnaltrexone bromide subcutaneous injection (RELISTOR) for the treatment of opioid-induced constipation in adults, according to a Valeant Pharmaceuticals International media release.
    • 05 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top